Gourmet is a reversible uric acid crystal abnormal deposition disease。Purine metabolism disorders can cause hyperuricemia，and therefore causes repeated gout acute arthritis、Gourmet Stone Deposition、Gourmet stone chronic arthritis and joint malformations，Frequently affects the formation of chronic interstitial nephritis and uric acid kidney stones。Hyperuricemia and gout still causes the independent risk factors of coronary heart disease and cerebral thrombosis。

 

  The incidence of gout from all over the world is large，There are 0.13%~ 0.37%，There are also 10%of New Zealand's gross profit adult men。After the 1980s，With the improvement of living standards，The incidence of gout in China also Stake Sports Bettingshows a rapid rise。Due to goutless root treatment drugs，Currently clinical anti -painstick wind medicine is used in autumn water pheasant、Non -Symatic Anti -inflammatory drugs、hormones、Promoting uric acid excretion medicine and inhibitory uric acid synthetic medicine。Acute Seizure with Plosth、Non -steroidal anti -inflammatory drugs; the relief period is mainly used to promote uric acid excretion medicine、Inhibiting uric acid synthetic medicine。Mine Net Anti -gouting Preparation Market Foreign Lumps，The rapid growth of gout anti -wind drugs in the past five years，2015 increased by 42%。

 

 

 

  Chinese market old medicine

 

  Quickly rising relative to the incidence，Update of the treatment of drugs is relatively lagging，The market is still mainly old medicine such as pheasant pylomine and benzidelon。

 

 

  Penalrine Malon was first successfully developed by French companies in the 1960s，After the 1970s, they have been approved to be listed in Germany and France，The mechanism is to block the re -absorption of uric acid in the renal tube、Promote uric acid excretion。Due to the side effects of its liver and kidney and other aspects，It is not the mainstream in the European and American market，The market is mainly Germany、Japan and Singapore and other Asian countries are the main。Penzide Malong entered China in 2000，At present, only one imported enterprise and 4 domestic companies such as Chengdu Huashen produce related preparations。less information in the research aspect。

 

  Alcohol and collaterals of autumn water are also old medicines。Allopurinol is a new molecular entity stake sports betting appapproved by the FDA priority review in 1966; autumn water porttic appeared in the FDA approval information in 1961，It is a compound compound with propyl Shu Shu。In our country，Qiu Shui Shinkinine has more than a dozen companies such as Taiwan Jingde Pharmaceutical and domestic Yunnan Botanical Pharmaceutical Industry;、Capsule agent slow -release preparations and other dosage forms，Production companies have more than a dozen companies including Chongqing Qingyang but have no imports。In terms of preparation innovation，Subvanol has a slow -release preparation and a compound preparation formed with the combination of benzinemon，Let the old medicine have a new life。

 

  New drugs in the world in the past ten years

 

  Although these drugs are the main market for the market，However, it is difficult to avoid problems such as the ideal effect and great side effects。

 

  2009，FDA approved Takeda for the treatment of high urea and ginseng disease.，Its mechanism is to reduce the concentration of serum uric acid by inhibiting uric acid synthesis。It is the first drug approved in the United States in the past 40 years，2012 was recommended by the "Guidelines for Hypertrophic Acidal Penal Diagnosis and Treatment" as a first -line medication。non -Tiss is a new type of illumin oxidase inhibitor，Its uric acid reduction effect is equivalent to allopurinol，Studies have shown that the medicine caused by the drug is significantly lower than that of allopurinol。This type of first -line medication that has only been approved by the past 40 years，The feedback given by the market is positive，2015 non -Tiss's global sales of 33.2 billion yen，increased by 23.4%year -on -year。

 

  stake betting appMay and July 2016，FDA gives Mailan and Alembic Pharmaceutical Non -Tiss's temporary approval，to meet the needs of the market。2013 CFDA approves Hangzhou to raise heart、Jiangsu Wanbang Biotechnology and Jiangsu Hengrui Production Non -Tisp Film，Start the practice of the drug in the domestic market。In just two years, the non -Tiss market has obtained a leap -up growth，Under the condition that the product has not entered the medical insurance，Sample hospital sales rose directly from more than 200,000 yuan in 2013 to more than 20 million yuan in 2015; and its market share rapidly increased，It also reminds the market's strong demand for new types of anti -windy drugs。

 

 

  December 2015，FDA approves Astrampic (LESINURAD) for treatment of adult gout patients。LESINURAD is a selective re -absorbent inhibitor，can reduce the generation of uric acid，At the same time, increase the excretion of uric acid at the same time。As the first selective uric acid absorption inhibitor，It can be used with eblotic oxidase inhibitors & mdash; & mdash;，Provided a new treatment selection for patients。February this year，Zurampic has also been approved by the European Union。

 

  Compared to the allecine oxidase inhibitors and uloric, the hydraulic acid content in the blood is both，Krystexxa, which was launched in 2010, is an enzyme，Uric acid can be converted into harmless chemicals，and excrete the body with urine，to reduce uric acid content。Krytexxa has been hovering at a lower level due to sales after listing，The company has to apply for bankruptcy protection，This leads to the withdrawal of the EU market。

 

 

  Conclusion & lt; & lt; & lt;

 

  stake sports betting appSome institutional estimates，With the listing of new anti -gangsters，Global Anti -Optical Anti -Wind Pharmaceutical Market will usher in rapid development。But，Currently in my country, except autumn waters and non -，The other three types of anti -gangsters approved by Europe and the United States in recent years have not been listed in my country and have no enterprise declaration。How to keep up with this round of rapid development becomes the focus of researchers' thinking。